Merck vs. AstraZeneca: Which Oncology Giant Reigns Supreme?

AstraZeneca and Merck are both major pharmaceutical companies with a strong presence in oncology. Merck's Keytruda is a top-line driver, with sales of $23.3 billion in the first nine months of 2025. Merck has a solid pipeline, including new vaccines and drugs with blockbuster potential, and has acquired Verona and Cidara Therapeutics to expand its portfolio. AstraZeneca also has a diverse portfolio and a solid presence in immunology, rare diseases, vaccines, and cardiovascular and respiratory. Both companies face challenges, but Merck's Keytruda and diversified pipeline make it a better investment option.